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Most cases of cystic fibrosis (CF) are caused by the deletion of a single phenylalanine
residue at position 508 of the cystic fibrosis transmembrane conductance regulator (CFTR).
The mutant F508del-CFTR is retained in the endoplasmic reticulum and degraded, but can
be induced by low temperature incubation (29˚C) to traffic to the plasma membrane where
it functions as a chloride channel. Here we show that, cardiac glycosides, at nanomolar
concentrations, can partially correct the trafficking of F508del-CFTR in human CF bronchial
epithelial cells (CFBE41o-) and in an F508del-CFTR mouse model. Comparison of the tran-
scriptional profiles obtained with polarized CFBE41o-cells after treatment with ouabain and
by low temperature has revealed a striking similarity between the two corrector treatments
that is not shared with other correctors. In summary, our study shows a novel function of
ouabain and its analogs in the regulation of F508del-CFTR trafficking and suggests that com-
pounds that mimic this low temperature correction of trafficking will provide new avenues
for the development of therapeutics for CF.
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INTRODUCTION
Cystic fibrosis (CF) is caused by mutations in the gene coding for
the cystic fibrosis transmembrane conductance regulator (CFTR),
which functions as a plasma membrane anion channel (Riordan
et al., 1989; Anderson et al., 1991; Kartner et al., 1991). The most
common CFTR mutation, F508del (Rommens et al., 1989), causes
retention of the mutant in the ER and its premature degrada-
tion by the proteasome (Cheng et al., 1990; Jensen et al., 1995).
Nevertheless, F508del-CFTR can form functional channels having
reduced activity (Dalemans et al., 1991), moreover its trafficking
is temperature sensitive and can be partially rescued in many cell
types by incubation at low temperature (≤29˚C; Denning et al.,
1992; Rennolds et al., 2008). It has been estimated that restoring
10–25% of wild-type CFTR (WT-CFTR) activity in patients would
alleviate the major symptoms of CF (Pilewski and Frizzell, 1999;
Zhang et al., 2009).
Cell-based assays for “correctors” of F508del-CFTR traffick-
ing have identified chemically diverse small molecules that correct
Abbreviations: CF, cystic fibrosis; CFBE, cystic fibrosis bronchial epithelial; CFTR,
cystic fibrosis transmembrane conductance regulator; CMAP, connectivity MAP;
COPII, vesicle coat proteins; ER, endoplasmic reticulum; ES, enrichment score;
FDR, false discovery rate; HA, hemagglutinin; HTS, high throughput screening;
Na+/K+-ATPase, sodium-potassium adenosine triphosphatase; NF-κB, nuclear
factor kappa-light-chain-enhancer of activated B cells.
trafficking with variable efficiency (Pedemonte et al., 2005; Van
Goor et al., 2006; Carlile et al., 2007). Some of these correctors
are thought to interact directly with CFTR by acting as stabiliz-
ing ligands or “pharmacological chaperones” (Loo et al., 2006;
Sampson et al., 2011) or on other known cellular targets, e.g.,
phosphodiesterases (Dormer et al., 2005; Robert et al., 2008) and
histone deacetylases (Hutt et al., 2010). However, for the majority
of correctors that have been described, neither the target nor the
mechanism of action are known (Lukacs and Verkman, 2012). We
have previously reported a novel cell-based HTS assay that mea-
sures the appearance of HA-tagged F508del-CFTR at the surface of
BHK cells (Carlile et al., 2007). Using this assay in a high through-
put screen we identified the cardiac glycoside ouabagenin, an
aglycone of ouabain, as a moderately potent corrector of F508del-
CFTR trafficking. Cardiac glycosides have long been used to treat
congestive heart failure and cardiac arrhythmia, and digoxin is still
prescribed for atrial fibrillation and atrial flutter (Prassas and Dia-
mandis, 2008). Cardiac glycosides bind to a highly conserved site
on human Na+/K+-ATPase alpha subunits with a K d of ∼18 nM
(Wang et al., 2001), which is expected to increase several fold in
the presence of physiological potassium concentrations. In cardiac
myocytes inhibiting the pump increases intracellular sodium and
reduces membrane sodium/calcium exchange, leading to elevation
of intracellular calcium and increased contractile force (Hoyer
et al., 2011). Moreover, clinical studies also suggest that cardiac
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glycosides inhibit cancer cell proliferation and have potential as
novel therapeutic agents against cancer (Newman et al., 2008).
In addition to its action as an inhibitor of Na+/K+-ATPase,
ouabain has a signaling function at low concentrations (1–10 nM)
that is independent of its effect on ion transport (Zhang et al.,
2006). Ouabain-bound Na+/K+-ATPase can trigger slow calcium
oscillations and NF-κB activation, thereby preventing cell death
and promoting the proliferation and viability of kidney proximal
tubule cells (Li et al., 2006). Interestingly, it has been reported that
digitoxin and other cardiac glycosides suppress IL-8-dependent
lung inflammation in CF lung epithelial cells (Srivastava et al.,
2004). The exact mechanisms by which cardiac glycosides modu-
late cell proliferation, inflammation, migration, and apoptosis are
not known (Aperia, 2007; Prassas and Diamandis, 2008).
Here we describe a novel function for ouabain and its analogs
which is linked to its signaling functions. Treatment with low
concentrations of ouabain resulted in the functional rescue of
F508del-CFTR in human CF bronchial epithelial cells, and also
in BHK cells and CF mice that are expected to be less sensitive
to ouabain inhibition. Moreover the mechanisms of correction
by ouabain and its analogs resemble those of low temperature
according to transcriptional profiling and analysis of the Connec-
tivity Map (CMAP) for F508del-CFTR trafficking in polarized
parental CFBE41o-cells. Significant connectivity was observed
between ouabain and low temperature transcriptional profiles
obtained in human CF bronchial epithelial cells and this rela-
tionship was confirmed by hierarchical clustering analysis of the
expression patterns.
These results reveal a new function for ouabain and its analogs
as regulators of F508del-CFTR protein trafficking and indicate
that cardiac glycosides act by mimicking low temperature rescue.
Transcriptional profiling provides insight into corrector mech-
anisms, and small molecules that mimic the low temperature
signature may be useful in developing therapeutics that correct
the trafficking defect in CF.
RESULTS
CARDIAC GLYCOSIDES CORRECT THE TRAFFICKING OF F508del-CFTR TO
THE CELL SURFACE
From our initial observation that ouabagenin, can correct F508del-
CFTR trafficking in BHK cells (Carlile et al., 2007), we selected a
panel of structurally related cardiac glycosides, including ouabain,
digoxin, and digitoxin (Figure 1A). To confirm that they increase
the trafficking of F508del-CFTR to the plasma membrane, we
treated BHK cells that express F508del-CFTR-3HA, and measured
the appearance of the HA epitope (Carlile et al., 2007). F508del-
CFTR-3HA was detectable at the cell surface after 2 h treatment
and after 24 h surface expression was increased about 20–30%
compared to time 0 h treated cells (Figure 1B).
CARDIAC GLYCOSIDES IMPROVE STABILITY AND TRAFFICKING OF
F508del-CFTR
The ER-retained glycoform of F508del-CFTR (band B,∼150 kD)
acquires terminal glycosylation (forming band C, ∼175 kD) and
traffics through the Golgi. We used immunoblotting to detect the
appearance of the mature glycosylated “band C” form of F508del-
CFTR in human CF bronchial epithelial cells (CFBE41o-) treated
with the individual cardiac glycosides and we evaluated their
efficacy in promoting trafficking correction (Figure 2A). We com-
pared the amount of band C with that found in cells treated at
low temperature (29˚C). Treatment with 100 nM ouabain, digi-
toxin, or digoxin, or 1µM ouabagenin, increased the steady-state
expression of immature (band B) and mature (band C) glyco-
forms of F508del-CFTR by 2- to 15-fold above vehicle control
(Figure 2B). We also observed an increase in core-glycosylated
F508del-CFTR (band B) upon treatment with the cardiac glyco-
sides (Figures 2A,B). There is an overall increase in CFTR protein
in the presence of cardiac glycosides, which could result in a“leaky”
ER. In order to assess whether the observed increase in trafficking
(band C) resulted from ER overload, we calculated the ratio of
band C/B (Hutt et al., 2010). We found that all the cardiac gly-
cosides (ouabain, digitoxin, and digoxin) increased the ratio of
C/B bands by three- to seven-fold compared with vehicle control
(Figure 2B) without affecting Na+/K+-ATPase protein expression
(Figure 2A). In Figure 2C, we compared our own anti-CFTR anti-
body (23C5) which we have utilized throughout this whole study
to the commercial anti-CFTR antibody (M3A7, from Chemicon).
The results show that both antibodies gave the similar results,
and our own anti-CFTR antibody can detect CFTR bands using
much less cell lysates compared with using commercial antibody.
To test if these cardiac glycosides have cytotoxicity on CFBE cells
or not, in Figure 3, we measured the cell proliferation after 24 h
of treatment with each individual cardiac glycoside on CFBE cells,
and the results showed that there is no significant cytotoxicity
on CFBE cells under 100 nM concentration of cardiac glycosides.
Taken together these results show a novel function for ouabain
and its analogs in F508del-CFTR folding and trafficking, beyond
its well-established role in ion homeostasis.
OUABAIN RESCUES F508del-CFTR FUNCTION
We next investigated if ouabain and its analogs could also rescue
F508del-CFTR channel activity. When CFBE/F508del-CFTR cells
were pre-treated with 100 nM ouabain, digoxin, digitoxin, or with
1µM ouabagenin for 24 h, the iodide efflux response evoked by
forskolin increased to levels that were 26–32% that of CFBE cells
expressing (WT-CFTR; Figure 4A).
These results were confirmed by measuring the short cir-
cuit current (see Materials and Methods) across polarized
CFBE/F508del-CFTR cells that had been pre-treated with 100 nM
ouabain for 24 h (Figures 4BI–V). A trans-epithelial chloride
gradient was imposed and the basolateral membrane was perme-
abilized using nystatin to ensure that the I sc response was mediated
by apical Cl− conductance (Robert et al., 2008). Representative
I sc recordings are shown for WT-CFTR monolayers (Figure 4BI)
and F508del-CFTR monolayers pre-incubated for 24 h with nor-
mal saline at low temperature (29˚C; Figure 4BII), with DMSO
vehicle at 37˚C (Figure 4BIII), or with 100 nM ouabain at 37˚C
(Figure 4BIV). Ouabain pre-treatment increased the forskolin
and genistein-stimulated I sc by∼1.7-fold compared with controls
(Figures 4BIII–V, P < 0.05). Chloride current was abolished by
the CFTR inhibitor CFTRinh-172 (Ma et al., 2002; Caci et al., 2008)
in each instance, confirming that the stimulated I sc was mediated
by CFTR channels. The magnitude of the CFTR-mediated cur-
rent induced by ouabain (n= 7) was 7.5% of that induced by
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FIGURE 1 | Cardiac glycosides induce trafficking of HA-tagged
F508del-CFTR to the cell surface. (A) Chemical structures of
cardiac glycosides tested in this study. (B) BHK cells expressing
F508del-CFTR-3HA were treated with 0.1µM ouabain, 0.1µM
digitoxin, 0.1µM digoxin, and 1.0µM ouabagenin for various time
points or with the vehicle control (0.1% DMSO), the cell surface
expression of CFTR were monitored by immunofluorescence
assay. Data are presented as percentage increase in surface CFTR
signal compared to controls (mean±SD of n=4; *P < 0.05,
**P <0.005).
low temperature (n= 6), which represents 1.4% of the current
measured in cells expressing WT-CFTR (n= 9; Figure 4BV).
The correction of F508del-CFTR trafficking and function by
ouabain pre-treatment was further evaluated in vivo using a
CF mouse salivary secretion assay. The F508del-CFTR traffick-
ing defect can be assayed functionally in the ileum and salivary
glands of this CF mouse model (French et al., 1996; Robert et al.,
2010). Homozygous F508del-CFTR mice and littermate WT con-
trols received continuous low doses of ouabain (0.01 mg/kg/day)
or vehicle for 48 h using a micro-osmotic pump implanted under
the skin. Salivary secretion was measured acutely by injection of
atropine and then isoprenaline into the cheek. Chronic exposure
to low levels of ouabain in vivo increased the salivary secretion
response by ∼5-fold (Figure 4C; ∗P < 0.04, n= 5). This value
corresponds to∼8.1% of the secretory response of littermate WT
control mice.
In summary, these data provide evidence that ouabain enhances
F508del-CFTR trafficking and channel activity in vitro in human
CF epithelial cells (CFBE41o-) and in vivo in F508del-CFTR
homozygous CF mice.
OUABAIN REDUCES THE ER CALCIUM STORES IN CFBE CELLS
Retention of misfolded proteins in the endoplasmic reticulum is
regulated by chaperone proteins, many of which require [Ca2+]
for optimal activity. Although controversial, several studies have
shown that [Ca2+] signaling is elevated in CF and that calcium
homeostasis in CF airway epithelial cells is disturbed and related
to the retention of F508del-CFTR proteins in the ER (Antigny
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FIGURE 2 | Cardiac glycosides correct trafficking of F508del-CFTR in CF
bronchial epithelial cells. (A) CFBE/F508del-CFTR cells were treated with
individual concentrations of ouabain, ouabagenin, digoxin, or digitoxin for 48 h
and the cell lysates were analyzed by western blotting using anti-CFTR,
anti-Na+/K+-ATPase alpha1, or anti-tubulin antibodies. CFTR band C and band
B are indicated by arrows. Tubulin is shown as a loading control. (B)
Quantification of the band intensities for (B) experiments expressed as fold
change vs. DMSO control. Values in the experiments described are presented
as means±SD (n=3). Means were tested for statistical significance using a
Student’s t -test (*P <0.05; **P <0.01). (C) The cell lysates from parental
CFBE41o- (P), CFBE/WT-CFTR (WT), and CFBE/F508del-CFTR (F508) cells
were analyzed using anti-CFTR antibody 23C5 (our own anti-CFTR antibody)
or M3A7 (from Chemicon). The molecular weight (kDa, kilodalton) of the
markers was shown on the side of the blot.
et al., 2008a,b). As the binding of nanomolar concentrations
of ouabain to Na+/K+-ATPase α subunits has previously been
reported to increase intracellular calcium (Li et al., 2006; Prassas
and Diamandis, 2008), we examined the calcium content of the
ER stores in WT-CFTR cells and in ouabain treated vs. untreated
CFBE/F508del-CFTR cells (see Materials and Methods). As shown
Frontiers in Pharmacology | Pharmacology of Ion Channels and Channelopathies October 2012 | Volume 3 | Article 176 | 4
Zhang et al. Rescue of F508del-CFTR by ouabain
FIGURE 3 | Nanomolar concentrations of cardiac glycosides have no
significant cytotoxic effects on CFBE cells at concentrations that correct
CFTR trafficking. (A–D) CFBE/F508del-CFTR cells were treated with different
concentrations of each cardiac glycoside for 24 h, the cell proliferations were
measured using the AlamarBlue assay. The bar graph shows the percentage
of the number of viable cells compared with the number of untreated cells,
which were assigned a value of 100% (data shown are the mean±SD of
n= 9; *P <0.05).
in Figure 5, the cytosolic calcium concentrations in CFBE/WT-
CFTR or in CFBE/F508del-CFTR cells are similar before adding
thapsigargin. However, after adding thapsigargin, the ER released
Ca2+ (ER calcium stores) in CFBE/F508del-CFTR cells were
about 32% higher than in CFBE/WT-CFTR cells (∗∗P < 0.008,
n= 6), and ouabain treatment reduced ER calcium stores in
CFBE/F508del-CFTR cells by ∼47% (∗P < 0.015, n= 6). Thus,
after 24 h of exposure to a low concentration of ouabain, ER cal-
cium stores in CFBE/F508del-CFTR cells were similar to those in
CFBE/WT-CFTR cells. And this normalization of ER [Ca2+] in
F508del-CFTR cells is also observed by low temperature rescue or
by other pharmacological corrections (Antigny et al., 2011).
CONNECTIVITY BETWEEN OUABAIN AND LOW TEMPERATURE
TRANSCRIPTIONAL PROFILES SUGGESTS A SIMILAR MODE OF ACTION
Genome wide transcriptional profiling can be used to infer simi-
larities between the mechanisms of action of different compounds.
The CMAP is a rich compendium of 6100 genome wide transcrip-
tional profiles from cultured human cells that have been treated
with 1309 bioactive small molecules, including ouabain, and other
cardiac glycosides. Gene signatures that show positive correlation
with reference profiles (instances) in the CMAP share functional
similarities and provide clues to the mechanisms of action of the
compounds (Lamb et al., 2006).
To explore the mechanism of F508del-CFTR correction by
ouabain, we used transcriptional profiling of parental CFBE41o-
cells subjected to different treatments. We generated gene expres-
sion profiles using two levels of stringency that were set using a
False Discovery Rate (FDR) of ≤0.01 and ≤0.05 (Benjamini and
Hochberg, 1995) and an absolute fold Change (absFC) >3. The
signatures used to query the CMAP (99 probes up- and 208 probes
down-regulated) were from polarized parental CFBE41o-cells
treated with ouabain for 24 h. As expected we detected ouabain
and six other cardiac glycoside reference profiles (instances) in
the CMAP with high confidence (Figure 6A, P-value= 0, enrich-
ment score (ES)= 0.995; ES, ranging from +1 means correlated;
−1 means anti-correlated). We then queried the CMAP with sig-
natures obtained under three well characterized conditions in
which F508del-CFTR trafficking is partially corrected: low tem-
perature rescue (29˚C) and the corrector compounds VRT-325
(Loo et al., 2006; Varga et al., 2008) and VX-809 (Van Goor et al.,
2011). Remarkably, the low temperature signature (FDR≤ 0.05;
384 probes up- and 329 probes down-regulated), recovered the
ouabain and the other six cardiac glycoside instances with very
high ESs (Figure 6B, P-value= 0, and ES= 0.942). At higher strin-
gency (FDR≤ 0.01; 81 probes up- and 74 probes down-regulated),
the low temperature signature remained tightly correlated with
the cardiac glycoside instances, including ouabain (Figure 6C,
P-value= 0, and ES= 0.972) suggesting that there is a strong sim-
ilarity. Conversely, when we queried the CMAP with signatures
derived from parental CFBE41o-cells treated with VRT-325 and
VX-809, which are thought to act as a pharmacological chaper-
ones that directly bind to F508del-CFTR, we found that the 24-h
signature for VRT-325 (FDR≤ 0.05; 20 probes up- and 139 probes
down-regulated) was negatively correlated with ouabain instances
and VX-809 24 h signature (FDR≤ 0.05; 97 probes up- and 64
probes down-regulated) null-correlated with ouabain instances
(Figure 6D).
We next examined a larger number of probes to explore the
broader transcriptional response to ouabain and low tempera-
ture (31914 probes/41000 Agilent probes, FDR≤ 0.05; Figure 7A)
and to confirm this relationship by measuring the similarity of
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FIGURE 4 | Ouabain rescues F508del-CFTR channel activity in in vitro
and in vivo assays. (A) CFBE/F508del-CFTR cells treated with ouabain,
ouabagenin, digoxin, and digitoxin for 24 h, and iodide efflux was monitored.
Data shown are the mean±SD of n=4 (*P <0.03; **P <0.006). (B)
CFBE/F508del-CFTR cells were treated with or without 0.1µM ouabain for
24 h and CFTR channel activity was measured by Ussing chamber assay. The
∆Isc stimulated by ouabain treatment was compared to low temperature
incubation (29˚C, 24 h) and to CFBE/WT-CFTR. Histogram showing the change
in Isc (∆Isc) after addition of forskolin+genistein, defined as the difference
between the sustained phase of the current response after stimulation and
the baseline immediately before stimulation. In the bar graph, data, are
presented as mean±SEM as compared to DMSO control [(I) n=9 for
CFBE/WT-CFTR cells; (II) n=6 for 29˚C treatment samples; (III) n=8 for
DMSO control; (IV) n=7 for ouabain; (V) *P <0.05; ***P <0.001]. (C)
Salivary secretion in wild-type mice (WT) or F508del-CFTR (F508del) mice
treated with vehicle alone or 0.01 mg/kg/day of ouabain for 2 days. Monitored
for 30 min following stimulation, results are expressed as the mean±SEM of
n=5 (*P < 0.04; **P <0.0004).
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FIGURE 5 | Ouabain reduced the ER calcium stores in CFBE cells.
CFBE/WT-CFTR and CFBE/F508del-CFTR cells were treated with, or
without-, 100 nM ouabain for 24 h. The cells were then loaded with
Fura-2/AM, and peak cytosolic Ca2+ concentration was measured as the
difference in Fura-2 fluorescence recorded before and after adding 2µM
thapsigargin. Data are mean±SD of n=6 (*P <0.015; **P <0.008).
the expression patterns. We considered the union of the genes
that were differentially expressed in each condition and discarded
those that were not changed across the four treatments (ouabain,
low temperature, VRT-325, and VX-809; FDR≤ 0.05) in an unsu-
pervised hierarchical clustering analysis (Eisen et al., 1998). In
the output from this type of analysis similar patterns of expres-
sion are grouped together. Ouabain and low temperature clus-
tered together based on the correlation coefficient and Euclidean
distance measurements suggesting they share a similar mecha-
nism of action, whereas VRT-325 and VX-809 form a distinct
group, again suggesting that they share a similar mode of action
(Figure 7B). To test the hypothesis that ouabain and low temper-
ature rescue operate via a similar mechanism, ouabain treatment
of CFBE/F508del-CFTR cells was combined with low tempera-
ture incubation in immunoblotting experiments (Figure 7C). No
increase in F508del-CFTR trafficking was observed with a com-
bination treatment, suggesting these treatments act in a similar
manner and are not additive. Conversely, VRT-325, which stabi-
lized the surface pool of F508del-CFTR as well as corr-4a (Varga
et al., 2008), were combined to low temperature treatment and they
further improved F508del-CFTR maturation in CFBE/F508del-
CFTR cells measured by immunoblotting (Jurkuvenaite et al.,
2010; Sondo et al., 2011).
OUABAIN AND LOW TEMPERATURE TREATMENT GENERATE SIMILAR
GENE EXPRESSION PROFILES
To gain insight into the molecular processes involved in the sta-
bility and trafficking of F508del-CFTR we analyzed the common
genes following ouabain and low temperature treatments using
the GeneGo Cystic Fibrosis platform (MetaCore™ by GeneGo,
Inc.). We obtained 3530 genes in common, 8963 unique genes
for ouabain and 687 unique genes for low temperature with
FDR≤ 0.05, and the intersection of ouabain and low tempera-
ture transcriptional signatures showed that 84% of the differen-
tially expressed genes at 29˚C were also differentially expressed
with ouabain treatment (Figure 8A, left panel). We performed
enrichment analysis to identify functional ontologies in MetaCore
with an associated P-value (Figure 8A, right panel). Enrichment
analysis consists of matching gene IDs of possible targets with
those in functional ontologies in GeneGo comparison experiments
workflow (Shmelkov et al., 2011).
Remarkably, among the common genes shared between
ouabain and low temperature treatments we found that the
Gene Ontology (GO) processes that were most highly enriched
were: Response to Endoplasmic Reticulum Stress (P = 1.11e−11),
Response to Unfolded Protein (P = 1.13e−11), Protein Transport
(P = 1.68e−11), and the more general Positive Regulation of Bio-
logical Processes (P = 1.61e−9; Figure 8A, right panel). These
results suggest that processes associated with the folding and
degradation of CFTR were at the interface between the two treat-
ments. To dissect this further we validated a subset of the 3530
common genes by real-time PCR (Figure 8B), selecting the ones
that were most differentially expressed by both treatments and
associated with the most enriched GO processes. After treat-
ment with ouabain and low temperature we observed a decrease
in the expression of chaperone genes such as HSPA8/Hsc70
and HSPA1L/Hsp70 that are involved in protein folding and
ER-associated degradation (Figure 8B, respectively 60 and 70%
reduced by ouabain, 80 and 60% reduced by low temperature; ∗P-
value< 0.05). To test if this altered level of mRNA could also be
detected at the protein level we measured the expression of Hsc70
and Hsp70 protein by immunoblotting (Figure 8C). The expres-
sion of Hsc70 and Hsp70 chaperones was decreased and correlated
with the appearance of mature F508del-CFTR (glycosylated form,
band C), and with increased levels of band B (core-glycosylated
form; Figure 8C). In contrast, expression of the Unfolded Pro-
tein Response (UPR) marker, HSPA5/BiP decreased with ouabain
treatment but remained unchanged at low temperature, while
ER chaperones such as calnexin (tested as a control) were unal-
tered by ouabain or low temperature (Figures 8B,C). We also
observed an increase in the SEC24A mRNA and protein expres-
sion (Figures 8B,C) following ouabain treatment. Sec24A (COPII
complex subunit) implicated in the binding of CFTR destined to
traffic from the ER (Routledge et al., 2010) was up-regulated by
ouabain treatment but not at low temperature (Figure 8C). At
the individual gene level, there were differences in the expression
levels between ouabain and low temperature but overall, the strik-
ing correlation obtained between the two signatures shows their
functional similarities.
DISCUSSION
Cardiac glycosides have been in clinical use for centuries to treat
heart failure, and the mechanism of their positive inotropic effect
is well characterized. Ouabain and other cardiac glycosides bind
Na+/K+-ATPase in cardiac myocytes and act by inhibiting its enzy-
matic activity or down-regulating its expression (Huang et al.,
1997; Hoyer et al., 2011). Cardiac glycosides can induce apopto-
sis and inhibit the growth of cancer cell lines and the pathway
to the clinic is expected to be short because the pharmacody-
namics and pharmacokinetics of cardiac glycosides are already
well-established (Prassas and Diamandis, 2008). Oleandrin, the
most promising first generation glycoside-based anticancer drug,
is presently in phase I clinical trials to determine the maximum-
tolerated dose and evaluate its effect on the pharmacokinetics on
chemotherapies administered concurrently (Yang et al., 2009).
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FIGURE 6 | Ouabain gene expression signature is highly correlated with
low temperature. Cartoon depicting the CMAP concept: pattern-matching
algorithms score each established profile for the direction (up- or
down-regulated) and strength (fold) of enrichment with the query signature
(Lamb et al., 2006). CMAP outputs of 100 nM ouabain (or other small
molecules) query signatures obtained in polarized parental CFBE41o-cells
treated for 24 h at 37˚C and polarized parental CFBE41o-cells treated for 24 h
at 29˚C (Low-Temp.). Probes generated a FDR≤0.05 and an absolute fold
change (absFC) >3 were included in the query signatures. Perturbagens are
ordered according to their estimated P -values (correlated means=0) and
corresponding connectivity scores, ranging from +1 (correlated) to −1
(anti-correlated). (A) The genomic changes induced in polarized parental
CFBE41o-cells by ouabain 24 h query signature is correlated with ouabain and
six cardiac glycosides previously established profiles in CMAP (instances).
(B) The genomic changes induced in polarized parental CFBE41o-cells by low
temperature 24 h specific-signature is highly ranked with ouabain and six
cardiac glycoside instances. (C) More stringent query signature (FDR≤0.01)
increases the ability of low temperature to recover ouabain instance in the
CMAP. (D) The genomic changes induced in polarized parental CFBE41o-cells
by 10µM VRT-325 and by 1µM VX-809 query signatures are respectively
weakly anti-correlated and null-correlated with the previously established
ouabain profile in CMAP.
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FIGURE 7 | Ouabain and low temperature rescue have a similar
mode of action. (A) Volcano plots of ouabain and low temperature gene
expression data. Values are presented as the log10 of FDR and fold
change. Green squares indicate up- and down-regulated probes for
CMAP query signatures for each treatment. Red squares indicate the
probes considered for each treatment in the unsupervised hierarchical
clustering according to FDR≤0.05. (B) Unsupervised hierarchical
clustering of ouabain, low temperature, VRT-325 and VX-809 expression
patterns (FDR≤0.05) using standard Correlation coefficient and Euclidian
distance as similarity measures. The distance between clusters was
computed according to complete linkage. (C) CFBE/F508del-CFTR cells
were treated with or without 0.1µM ouabain for 48 h at 29 or 37˚C, the
cell lysates were analyzed by immunoblotting with anti-CFTR or
anti-tubulin antibodies.
In contrast to the apoptotic effects of these drugs on cancer
cells, low concentrations of ouabain have also been shown to
stimulate the proliferation and inhibit cell death in normal cells
(Li et al., 2006). It has been reported that digitoxin and other
cardiac glycosides at sub-nanomolar concentrations mimic gene
therapy with CFTR in vitro and can suppress the hypersecretion
of IL-8 by cultured CF airway epithelial cells (Srivastava et al.,
2004). More recent data show that digoxin derivates attenuate
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FIGURE 8 |The effects of ouabain and low temperature on ER-related
chaperones. (A) Left panel: Venn diagram of the intersection between
ouabain and low temperature 24 h signatures according to a FDR≤0.05.
The numbers indicate distinct genes. The probability *P =0.0001 was
calculated using a hyper-geometric random variable. Right panel: Gene
Ontology (GO) cellular processes pie chart of 3530 genes in common
between ouabain and low temperature 24 h treatments. (B) The total RNA
previously extracted for the microarray analysis was tested by real-time
PCR using the individual primers for the gene expressions of HSPA8,
HSPA1L, HSPA5, SEC24A, and CANX. Data are presented by the fold
change of gene expression vs. DMSO control with mean±SEM of n=3
(*P <0.05) (C) CFBE/F508del-CFTR cells were treated with 0.1µM
ouabain or 29˚C (Low-Temp.) for 6, 24, or 48 h, then the cell lysates were
analyzed by immunoblotting using the individual antibodies. The bar graph
shows quantification of the band intensities for blots expressed as fold
change vs. Time 0 h control. Values in the experiments described are
presented as means±SD (n=3). Means were tested for statistical
significance using a Student’s t -test (*P <0.05).
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inflammatory lymphocyte function and autoimmune diseases
(Huh et al., 2011).
Na+/K+-ATPase, the target of cardiac glycosides can, in the
presence of nanomolar concentrations of ouabain, act as a signal
transducer. For instance, it has been reported that ouabain-bound
Na+/K+-ATPase can, independent of its ion transport function,
induce multiple signaling pathways including c-Src and intra-
cellular calcium oscillations (Zhang et al., 2006). Several studies
have shown that [Ca2+] is elevated in CF and becomes normal-
ized when the trafficking of F508del-CFTR is corrected by small
molecules or low temperature (Norez et al., 2006, 2009; Antigny
et al., 2008a). The relationships between CFTR and calcium sig-
naling have recently been reviewed (Antigny et al., 2011), however
the role of [Ca2+] in protein biogenesis and trafficking remains
incompletely understood. We confirmed the elevation of ER cal-
cium stores in CF cells and showed that ouabain reduces store
calcium to normal levels in CFBE cells expressing F508del-CFTR
(Figure 5).
Here, we demonstrate that nanomolar ouabain increases
F508del-CFTR trafficking to the cell surface and partially restores
its function in a human CF bronchial epithelial cell line. Ouabain
has this effect without causing substantial inhibition of Na+/K+-
ATPase protein expression or cell viability. Moreover, our in vivo
results also showed functional rescue of mutant CFTR by ouabain
in CF mice and the value corresponds to ∼8.1% of the secre-
tory response of littermate WT control mice and without affecting
the mice body weight (control group: starting, 26.36± 2.49 g;
after 48 h, 26.53± 2.63 g, P > 0.2; ouabain treated group: start-
ing, 26.98± 2.39 g; after 48 h 27.29± 2.33 g, P > 0.2). Thus our
data raise the possibility that cardiac glycosides not only increase
total CFTR protein expression, but may also increase the fold-
ing yield and trafficking of F508del-CFTR. Ouabain thus joins a
growing list of F508del-CFTR corrector compounds that act by
modulating proteostasis (Calamini et al., 2012) rather than by act-
ing as pharmacological chaperones that bind to F508del-CFTR
(Sampson et al., 2011). Considering the inhibition function of
cardiac glycosides on inflammation in cultured CF airway epithe-
lial cells (Srivastava et al., 2004), also associating the long history
of cardiac glycosides have being used in clinical treatment, it sug-
gests that ouabain and other cardiac glycosides may have potential
therapeutic perspectives for CF patients.
Transcriptional profiling analysis and the CMAP uncovered
interesting similarities between very different corrector mecha-
nisms (Lamb et al., 2006). We proved the ability and reliability
of the CMAP to connect our ouabain signature and the ouabain
reference profiles already present in the CMAP collection, and
then found that the resulting transcriptional profile obtained by
ouabain treatment resembled that produced by low temperature
(29˚C) suggesting a similar mechanism of action. The CMAP is
a resource that can be used to discover functional connections
with a limited number of probes that are up- or down-regulated
(≤1000 probes). To better identify the state of the CFBE41o-
cells throughout their responses to ouabain, low temperature,
VRT-325 and VX-809, we applied an unsupervised hierarchical
cluster analysis to obtain a direct measure of similarity of parental
CFBE41o-expression patterns. In this approach, a larger number
of probes, comparing the ones queried in CMAP, were computed
using standard Correlation coefficient and Euclidian distance as
measures of similarity. The output groups together genes with
similar patterns of expression by a direct measure of similarity and
probes which encode for genes that are co-expressed share com-
mon mechanisms. We integrated VRT-325 and VX-809 profiles
in the clustering analysis not only because both these compounds
are thought to bind to F508del-CFTR (Loo et al., 2006; Varga
et al., 2008; Van Goor et al., 2011) but also to delineate different
“categories” of correctors based on shared mechanisms of action.
The addition of this condition enhances our observation by which
ouabain and low temperature share a common mechanism and
VRT-325 cluster together with VX-809 and we supported our
mode of action predictions based on gene expression profiles by
combination treatments.
Our study indicates that ouabain and low temperature rescue
of F508-CFTR may involve the down-regulation of chaperones
(HSPA8/Hsc70 and HSPA1L/Hsp70), thereby reducing F508del-
CFTR degradation; and the up-regulation of COPII components
for vesicular export to the Golgi. These two heat shock proteins
play important roles in the biosynthesis and degradation of CFTR
and it has been shown that a decrease in expression of Hsc70
(in association with the co-chaperone CHIP) results in decreased
degradation of F508del-CFTR (Rab et al., 2007; Matsumura et al.,
2011). Moreover, we found an increased expression of SAR1A
(COPII complex subunits; see Supplementary Material) by low
temperature incubation. SAR1A, together with SEC24A, which is
up-regulated by ouabain, led to anterograde export of the binding
protein to the Golgi (Yoo et al., 2002; Wang et al., 2008). The inter-
section of ouabain and low temperature transcriptional responses
indicates that 84% of the genes that are differentially expressed at
29˚C are also differentially expressed with ouabain (Figure 8A, left
panel). Thus, ouabain may shift the cells to a “permissive” state by
mimicking low temperature, thus correcting the F508del-CFTR
folding and trafficking defect.
Dissection of the molecular events that underlie rescue by low
temperature and mimicking it with a small molecule may be a
strategy to identify CF therapeutics. Galietta and colleagues have
shown using CFBE41o-cells that low temperature can synergize
with correctors such as corr-4a and VRT-325 (Sondo et al., 2011).
Therefore our finding suggests that combination treatments that
include ouabain may also be synergistic in the treatment of CF.
In summary, our study shows that low concentrations of
ouabain can rescue F508del-CFTR by mimicking low tempera-
ture rescue in human CF bronchial epithelial cells. Apart from
pharmacological chaperones that bind directly to F508del-CFTR
the target of and the mechanism of action of most correctors is
unknown. Certainly cardiac glycosides are being investigated for
use as a cancer therapeutic and for other diseases (Prassas and Dia-
mandis, 2008). We predict that the Na+/K+-ATPase or its down-
stream pathway will be a good place to search for F508del-CFTR
correctors.
MATERIALS AND METHODS
CELL CULTURE AND TRANSFECTIONS
The parental CFBE41o-cell line was originally developed by
immortalization of CF (F508del/F508del) bronchial epithelial cells
by Dr. D. Gruenert (Kunzelmann et al., 1993). The mutated
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protein is expressed at low levels in this cell line, therefore two
derivatives were generated by transduction using the TranzVector
lentivirus system (Wu et al., 2000) to create CFBE/WT-CFTR and
CFBE/F508del-CFTR cell lines in which the CFTR protein can be
detected by immunoblots. Those cells were generously provided
by Dr. J. P. Clancy (University of Alabama, Birmingham) and cul-
tured in EMEM medium supplemented with 10% FBS. Polarized
CFBE41o-cells were cultured initially under liquid–liquid condi-
tions, then allowed to polarize at the air–liquid interface. BHK cells
stably expressing F508del-CFTR-3HA were cultured as described
previously (Carlile et al., 2007).
THE CELL-BASED TRAFFICKING ASSAY
The surface expression of CFTR was measured as described pre-
viously (Carlile et al., 2007). BHK cells stably expressing F508del-
CFTR-3HA (bearing a 3HA-epitope tag in the fourth extracellular
loop) were treated with cardiac glycosides. Cells were fixed with
4% paraformaldehyde for 15–20 min at 4˚C and incubated with
monoclonal anti-HA antibody (Sigma, Canada) solution con-
taining 1% FBS at 4˚C overnight. After washing, the plates were
analyzed using a plate reader (Analyst™ HT 96.384, Biosystems,
USA; 488 nm excitation,510 nm emission) to measure background
fluorescence, then incubated with anti-mouse IgG antibody con-
jugated with FITC (Sigma, Canada) at a dilution of 1:100 for 1 h.
The cells were washed, then incubated with 100µl of PBS, and
reanalyzed. The mean fluorescence of 12 mock (DMSO) treated
wells was used as the background signal and designated 0% cell
surface signal. The surface CFTR signal of cells expressing WT-
CFTR on the same plate was designated 100%. The compound
treated cell fluorescent signal was then given a percentage value
relative to these two controls. Control experiments indicated that
the vehicle did not affect trafficking when added alone (data not
shown).
IMMUNOBLOTTING AND ANTIBODIES
Cells were lysed in RIPA buffer containing 1% Triton X-100,
0.1% SDS, 150 mM NaCl, 20 mM Tris-HCl (pH 8.0), and 0.08%
deoxycholic acid, and lysates were separated by 6% SDS-PAGE
and transferred to nitrocellulose filters. The filters were probed
with monoclonal anti-tubulin (Sigma), anti-CFTR (monoclonal
antibody 23C5, P. Määttänen, M. Mirza, and D. Y. Thomas,
unpublished results), anti-CFTR (M3A7, Chemicon), anti-BiP
(BD Transduction Laboratories), anti-Hsp70 (Stressgen), rabbit
polyclonal anti-calnexin (kindly provided by Dr J. J. Bergeron,
McGill University), rabbit anti-Sec24A (Novus Biologicals), and
rabbit anti-Hsc70 antibodies (StressMarq). Horseradish peroxi-
dase (HRP)-conjugated secondary antibodies were used and blots
were developed using the ECL detection system (Roche, Germany)
and exposed to film (Amersham). The films were scanned and ana-
lyzed by densitometry using Photoshop (Adobe, Inc.). Quantifi-
cation of the band intensities for Figures 2B and 8C experiments
expressed as fold change vs. DMSO control and normalized by
tubulin bands.
CYTOTOXICITY ASSAY
The cytotoxic effects of ouabain or other cardiac glycosides
(from Sigma) were determined by using the colorimetric
AlamarBlue™ (Biosource, Camarillo, CA, USA) assay, according
to the manufacturer’s instructions. Briefly, cells were plated in
triplicate at a density of 3× 105 cells/per well in 96-well plates and
cultured overnight. Cells were then treated with the different con-
centrations of ouabain or other cardiac glycosides for 24 h. The
medium was removed after 24 h and cells were incubated in fresh
medium at 37˚C, 5% CO2 for 4 h. At the end of the 4-h incuba-
tion, 10µl of AlamarBlue was added to each well and incubated
at 37˚C, 5% CO2 for 18 h. Absorbance was measured at 570 and
600 nm and medium without cells was used as blank. Percent sur-
vival was quantified according to the manufacturer’s instructions
and the untreated sample was set to 100%. Final percent sur-
vival was averaged from three triplicates from three independent
experiments.
STATISTICS
Values in the experiments described are presented as means± SD.
Means were tested for statistical significance using the Student’s
t -test.
IODIDE EFFLUX ASSAYS
Cystic fibrosis transmembrane conductance regulator channel
activity was assayed by measuring iodide efflux with a robotic
liquid handing system (BioRobot 8000, Qiagen, USA) using Qia-
gen 4.1 Software as described previously (Robert et al., 2008).
Cells were seeded in 24-well plates allowed to reach 100% con-
fluence, and treated with drug or vehicle for an additional 24 h.
Cells were then incubated in iodide loading buffer [136 mM
NaI, 3 mM KNO3, 2 mM Ca(NO3)2, 11 mM glucose, and 20 mM
Hepes pH 7.4] for 1 h at 37˚C, then washed with efflux buffer
[136 mM NaNO3, 3 mM KNO3, 2 mM Ca(NO3)2, 11 mM glu-
cose, and 20 mM Hepes, pH 7.4] and the appearance of I− was
measured after replacing the buffer at 1 min intervals before and
during stimulation with 50µM genistein and 10µM forskolin
using an iodide-sensitive electrode (Orion Research, Inc., Boston,
MA, USA). Relative iodide efflux rates were calculated from the
difference between the maximal (peak) iodide concentration dur-
ing stimulation and the minimal iodide concentration before
stimulation.
USSING CHAMBER STUDIES
Cystic fibrosis transmembrane conductance regulator channel
activity was measured in Ussing chambers as described previously
(Robert et al., 2010). Briefly, 2× 106 cells (CFBE/WT-CFTR or
CFBE/F508del-CFTR cells) were seeded onto fibronectin-coated
Snapwell 12-mm inserts (Corning Incorporated, Life Sciences, NY,
USA) and the apical medium was removed the following day
to create an air–liquid interface. Trans-epithelial resistance was
monitored using an EVOM epithelial volt ohm meter (World
Precision Instruments, Sarasota, FL, USA) and cells were used
when the trans-epithelial resistance of the monolayer was 300–
400Ω cm2. In some experiments, CFBE/F508del-CFTR monolay-
ers were grown at 29˚C or treated with a test compound at 37˚C
for 24 h before being mounted in chambers and voltage-clamped
using a VCCMC multichannel current-voltage clamp (Physiologic
Instruments, San Diego, CA, USA). Apical membrane conduc-
tance was functionally isolated by permeabilizing the basolateral
membrane with 200µg/ml nystatin and imposing an apical-to-
basolateral Cl− gradient. The apical bathing solution contained
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115 mM NaCl, 25 mM NaHCO3, 1.2 mM MgCl2, 1.2 mM CaCl2,
2.4 mM KH2PO4, 1.24 mM K2HPO4, 10 mM mannitol (pH 7.4
with NaOH). The basolateral bathing solution contained 1.2 mM
NaCl, 115 mM Na-gluconate, 25 mM NaHCO3, 1.2 mM MgCl2,
4 mM CaCl2, 2.4 mM, KH2PO4, 1.24 mM K2HPO4, 10 mM glu-
cose (pH 7.4 with NaOH). CaCl2 was increased to 4 mM to
compensate for its chelation by gluconate. The apical solution con-
tained mannitol instead of glucose to eliminate current mediated
by Na+-glucose cotransporters. Successful permeabilization of the
basolateral membrane under these conditions was obvious from
the reversal of I sc. Solutions were continuously gassed and stirred
with 95% O2-5% CO2 and maintained at 37˚C. Ag/AgCl refer-
ence electrodes were used to measure trans-epithelial voltage and
pass current. Pulses (1 mV amplitude, 1 s duration) were imposed
every 90 s to monitor resistance. The voltage clamps were con-
nected to a PowerLab/8SP interface (ADInstruments, Colorado
Springs, CO, USA) for data collection. Ten micromolars forskolin
+50µM genistein were added to the apical bathing solution to
activate CFTR.
SALIVARY SECRETION
The salivary secretion assay was performed as described (Best
and Quinton, 2005). Briefly, homozygous ∆508-CFTR mice
(Cftrtm1 Eur) and WT mice were 10–12 weeks old and when used
weighed 20–25 g. A micro pump (Alzet Model 1003D) was fixed
under the skin on the back of mouse to deliver a very low dose
of ouabain (0.01 mg/kg/day) or vehicle for 48 h. Mice were anes-
thetized using ketamine and diazepam and 1 mM atropine was
injected subcutaneously into the left cheek to block cholinergic
responses. After absorbing any saliva with Whatman filter paper,
100µM isoprenaline was injected at the same site with 1 mM
atropine to induce secretion and saliva was collected on filter
paper every 3 min for 30 min. Samples were immediately sealed
in a pre-weighed vial and the saliva secretion rate and the total
amount were normalized to mouse weight. All procedures were
performed according to guidelines developed by the Canadian
Council on Animal Care and the protocol was approved by the
McGill University Animal Care Committee.
ER CALCIUM STORE MEASUREMENTS
Thapsigargin-releasable ER calcium was calculated as the differ-
ence in cytoplasmic calcium measured before and after the addi-
tion of 2µM thapsigargin to cells in Ca2+-free buffer. In brief, the
cells were grown and treated with or without 0.1µM ouabain for
24 h, then 2× 106 cells (CFBE/WT-CFTR or CFBE/F508del-CFTR
cells) were harvested and washed in Ca2+-free buffer (20 mM
HEPES, pH 7.4, 143 mM NaCl, 6 mM KCl, 1 mM MgSO4, 0.1%
glucose, 0.1% bovine serum albumin, 250 mM sulfinpyrazone).
The cells were resuspended in 200µl of calcium-free buffer con-
taining 0.02% pluronic acid and subsequently loaded with the cell-
permeable fluorescent indicator Fura-2/AM at 3 mM for 30 min
at 37˚C. After a final wash, the cells were resuspended in Ca2+-free
buffer and a 340/380-nm excitation ratio at a 510-nm emission
wavelength were obtained using a LS 50B PerkinElmer Life Sci-
ences luminescence spectrophotometer. The fluorescence ratio
(340/380) was measured in cells treated with 2µM thapsigar-
gin and the Fura-2 ratio values converted to [Ca2+] according
Grynkiewicz et al. (1985). The peak of thapsigargin-releasable
[Ca2+]cyto was calculated as the difference in cytoplasmic calcium
measured before and after the addition of 2µM thapsigargin to
cells in Ca2+-free Hanks’ buffer.
MICROARRAY ANALYSIS
Polarized parental CFBE41o-cells cultured at the air–liquid
interface were used for microarray assays. RNA samples were
extracted in 1 ml TRIzol Reagent (Invitrogen, USA), quantifi-
cated by spectrophotometry (Nanodrop, USA), and RNA integrity
was assessed using an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA, USA). Only samples with an RNA
integrity number (RIN) ≥ of 8 were used for amplification.
Total RNA (1 mg) was subjected to two rounds of amplifi-
cation using the Amino Allyl MessageAMP II aRNA amplifi-
cation kit (Ambion, Applied Biosystems, USA). The integrity
and quantity of the aRNA was revaluated by Nanodrop and
Agilent Bioanalyzer, and coupled to Cy3 and Cy5 (Amersham
Biosciences, UK). Whole Human Genome 44 K arrays (Agi-
lent Technologies, product G4112A) were used for all experi-
ments. RNA samples (825 ng/each) were subjected to fragmen-
tation followed by 16 h hybridization, washing, and scanning
(Agilent Technologies, model G2505B) according to the man-
ufacturer’s protocol (manual ID #G4140-90030). Samples were
hybridized against Universal Human Reference RNA (Strata-
gene, ID #740000, La Jolla, CA, USA). Duplicate hybridiza-
tions were performed for each sample using reverse-dye labeling.
Arrays were washed according to manufacturer’s recommenda-
tions, scanned using an Agilent dual-laser microarray scanner
(Model G2505B), and Cy5/Cy3-signals were quantified using
Agilent’s Feature Extraction software (v.7.11) with the default
parameters.
Microarray quality control reports generated by the Agi-
lent Feature Extraction software were used to detect hybridiza-
tion artifacts. Probe level raw intensities were processed using
R/BioConductor and Limma package (Gentleman et al., 2004).
Data were background corrected using “normexp” limma method
and normalized in two steps: loess normalization within-array to
correct systematic dye-bias and quantile normalization between–
arrays to detect systematic non-biological bias. Ratios represent-
ing the relative target mRNA intensities compared to Universal
Human Reference RNA probe signals were derived from normal-
ized data. To remove “batch effects” across microarray experi-
ments we adjusted the data using the empirical Bayes method
available at: http://biosun1.harvard.edu/complab/batch/ (Johnson
et al., 2007). PCA plots and Clustering trees of normalized adjusted
intensities were drawn for each time-point specific sets of samples
to confirm the robustness of the method used.
To find differentially expressed genes (treatment vs. control),
a t -test was applied for each time-point. For each P-value, the
Benjamini–Hochberg procedure was used to calculate the FDR
(Benjamini and Hochberg, 1995). Genes were considered to be dif-
ferentially expressed if the corrected FDR≤ 0.05 (while controlling
the expected FDR to no more than 5%). Unsupervised hierarchi-
cal clustering was performed on normalized data (FDR≤ 0.05),
with complete linkage and Euclidian and Pearson’s correlation
distances.
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FUNCTIONAL CATEGORY ENRICHMENT ANALYSES
Identification of overrepresented functional categories (pathways
and cellular processes) was performed per treatments using the
complete set of differentially expressed genes (FDR≤ 0.05) in
the MetaCore™ suit (Version 6.1; GeneGo, Inc., St. Joseph, MI,
USA; Nikolsky et al., 2005). The functional analysis were based on
MetaCore’s proprietary manually curated data base of CF specific
contents (Nikolsky et al., 2009).
REAL-TIME PCR
Total RNA was extracted from cells using TRIzol Reagent
(Life Technologies, Inc., Burlington, ON, Canada), and the
cDNA was synthesized using AffinityScript QPCR cDNA Syn-
thesis Kit (Stratagene, La Jolla, CA, USA). Real-time PCR
was performed using a Stratagene Mx3005PTM system (Strat-
agene, La Jolla, CA, USA) as follows: 20µl reaction solu-
tion contained 10µl SYBR Green Supermix (Bio-Rad Labo-
ratories, Inc., Hercules, CA, USA); 0.4µl sense and reverse
primer (25 ng/µl); 2µl diluted cDNA; 7.2µl nuclease-free water.
For the cross-validation real-time PCR experiments we used
the same total RNA extracted for the microarray assays. The
primer sequences were designed according to the GenBank™
accession numbers: GAPDH NM_002046; CFTR NM_000492;
HSPA8 NM_006597; HSPA1L NM_005527; HSPA5 NM_005347;
SEC24A NM_021982; and CANX NM_001746. The subsequent
data analysis was performed using MxPro™ QPCR Software
followed by comparative quantification real-time PCR. Gene
expression levels were normalized to GAPDH gene expression
and compared with untreated control, which was assigned a
value of 1.
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